Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer (Q27851588)

13 November 2016

title

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer (English)

1 reference

PubMed

PubMed publication ID

20979469

non-small-cell lung carcinoma

13 November 2016

main subject

0 references

20

Mari Mino-Kenudson

0 references

Leena Gandhi

Leena Gandhi

19

0 references

Daniel B Costa

Daniel B Costa

10

0 references

Robert G. Maki

Robert G Maki

6

0 references

Ravi Salgia

28

Ravi Salgia

0 references

Pasi A Jänne

9

Pasi A Jänne

0 references

Mark J Ratain

23

Mark J Ratain

0 references

Daniel Haber

26

Daniel A Haber

0 references

Lecia V Sequist

17

Lecia V Sequist

0 references

Yung-Jue Bang

2

Yung-Jue Bang

0 references

A John Iafrate

31

A John Iafrate

0 references

Jeffrey A Engelman

16

Jeffrey A Engelman

0 references

Keith D Wilner

27

Keith Wilner

0 references

Eunice L Kwak

1

Eunice L Kwak

0 references

D Ross Camidge

3

D Ross Camidge

0 references

Jeffrey W Clark

30

Jeffrey W Clark

0 references

Benjamin J Solomon

5

Benjamin Solomon

0 references

Alice T Shaw

4

Alice T Shaw

0 references

James G Christensen

25

James G Christensen

0 references

Marileila Varella-Garcia

11

Marileila Varella-Garcia

0 references

author name string

Sai-Hong I Ou

7

0 references

Bruce J Dezube

8

0 references

Woo-Ho Kim

12

0 references

Thomas J Lynch

13

0 references

Panos Fidias

14

0 references

Hannah Stubbs

15

0 references

WeiWei Tan

18

0 references

Greg C Wei

21

0 references

S Martin Shreeve

22

0 references

Jeffrey Settleman

24

0 references

Geoffrey I Shapiro

The New England Journal of Medicine

29

0 references

language of work or name

English

0 references

publication date

28 October 2010

0 references

published in

0 references

volume

363

0 references

issue

18

0 references

page(s)

1693-703

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Activating mutations in ALK provide a therapeutic target in neuroblastoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Identification of ALK as a major familial neuroblastoma predisposition gene

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

The emerging normal and disease-related roles of anaplastic lymphoma kinase

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Toxicity and response criteria of the Eastern Cooperative Oncology Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

EML4-ALK fusion lung cancer: a rare acquired event

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Second-line treatment of advanced non-small cell lung cancer

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3014291

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20979469